论文部分内容阅读
目的:探讨甘精胰岛素与格列美脲的联合应用在治疗2型糖尿病中控制血糖浓度、低血糖率方面的作用。方法:选择的对象为2011年5月~2013年4月在我院就诊的80例2型糖尿病患者,将其分成对照组和观察组,每组40例。对照组患者的治疗方案为:每天早餐前服用格列美脲,睡眠之前皮下注射低精蛋白胰岛素;观察组患者的治疗方案为:早餐前口服格列美脲,睡眠之前皮下注射甘精胰岛素。结果:2组患者空腹血糖浓度和餐后2小时血糖浓度在治疗之后都小于7.0mmol/L,两者之间没有显著性差异,P>0.05,2组患者的低血糖发生率,观察组明显低于对照组,P<0.05,有显著性差异。结论:甘精胰岛素联合格列美脲治疗2型糖尿病与常规治疗方案相比同样能够有效控制血糖水平,并且能显著降低低血糖的发生率,值得临床推广应用。
Objective: To investigate the effect of combination of glargine and glimepiride on the control of blood glucose and hypoglycemia in type 2 diabetes mellitus. Methods: 80 type 2 diabetic patients treated in our hospital from May 2011 to April 2013 were selected and divided into control group and observation group, 40 cases in each group. Patients in the control group were treated with glimepiride daily before breakfast and hypodermic insulin subcutaneously before sleep. Patients in the observation group were treated with glimepiride before breakfast and glargine subcutaneously before sleep. Results: Fasting plasma glucose and 2-hour postprandial plasma glucose concentrations in both groups were less than 7.0mmol / L after treatment, there was no significant difference between the two groups (P> 0.05). The incidence of hypoglycemia in 2 and 2 groups was significantly higher in observation group Lower than the control group, P <0.05, there was a significant difference. CONCLUSION: Glargine and glimepiride treatment of type 2 diabetes mellitus can effectively control blood glucose levels compared with conventional treatment, and can significantly reduce the incidence of hypoglycemia, worthy of clinical promotion and application.